601 results on '"Dunn, Kelly E."'
Search Results
52. Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype–genotype assessment
53. 1993. Donor-Derived Transmission of Candida species: 10-year Analysis from the OPTN ad hoc Disease Transmission Advisory Committee (DTAC)
54. Factors Associated with High-Risk Substance Use in Persons Receiving Psychiatric Treatment for a Primary Trauma- and Stressor-Related Disorder Diagnosis
55. Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients
56. Individual differences in human opioid abuse potential as observed in a human laboratory study
57. Increased neural activity in the right dorsolateral prefrontal cortex during a risky decision-making task is associated with cocaine use in methadone-maintained patients
58. Randomized comparison of two web-based interventions on immediate and 30-day opioid overdose knowledge in three unique risk groups
59. Voucher-Based Contingent Reinforcement of Smoking Abstinence among Methadone-Maintained Patients: A Pilot Study
60. Buprenorphine in the United States: Motives for abuse, misuse, and diversion
61. The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal
62. The risk for problematic opioid use in chronic pain: What can we learn from studies of pain and reward?
63. A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder
64. Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management
65. Virtual focus groups among individuals with use disorders: assessing feasibility and acceptability in an underserved clinical population.
66. Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype–genotype assessment.
67. Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats.
68. Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D
69. Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients
70. Challenges for Women Entering Treatment for Opioid Use Disorder
71. The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use
72. Novel methods for the remote investigation of emerging substances: Application to kratom.
73. Xylazine co-self-administration suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats
74. Fentanyl Absorption, Distribution, Metabolism, and Excretion: Narrative Review and Clinical Significance Related to Illicitly Manufactured Fentanyl
75. Clinically meaningful individual differences in opioid withdrawal expression.
76. Examining the paradoxical effects of kratom: a narrative inquiry
77. Operational definition of precipitated opioid withdrawal
78. Why aren't physicians prescribing more buprenorphine?
79. Randomized controlled trial of a computerized opioid overdose education intervention
80. Drug Legalization and Decriminalization Beliefs Among Substance-using and Nonusing Individuals
81. Opioid Overdose Experience, Risk Behaviors, and Knowledge in Drug Users from a Rural Versus an Urban Setting
82. Behavioral risk assessment for infectious diseases (BRAID): Self-report instrument to assess injection and noninjection risk behaviors in substance users
83. Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study
84. Bupropion Slow Release vs Placebo With Adaptive Incentives for Cocaine Use Disorder in Persons Receiving Methadone for Opioid Use Disorder
85. Iteration is not solving the opioid crisis, it’s time for transformation
86. OPTN required SARS‐CoV‐2 lower respiratory testing for lung donors: Striking the balance
87. A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal.
88. Can initial experiences with drugs predict future drug abuse risks?
89. Transplant of organs from donors with positive SARS‐CoV‐2 nucleic acid testing: A report from the organ procurement and transplantation network ad hoc disease transmission advisory committee
90. Xylazine Shifts the Fentanyl Dose-Response Curve Downward, Suppresses Demand Intensity, and Transiently Suppresses Acute Fentanyl Withdrawal: A Comparison to Lofexidine
91. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder
92. Comparison of methods to assess psychiatric medication adherence in methadone-maintained patients with co-occurring psychiatric disorder
93. Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation
94. The Public Health Challenge of Δ8-THC and Derived Psychoactive Cannabis Products.
95. Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients
96. Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use
97. Characterizing opioid withdrawal during double-blind buprenorphine detoxification
98. Wireless electroencephalography (EEG) to monitor sleep among patients being withdrawn from opioids: Evidence of feasibility and utility.
99. Social, psychological, and substance use characteristics of U.S. adults who use kratom: Initial findings from an online, crowdsourced study.
100. Assessment of Kratom Use Disorder and Withdrawal Among an Online Convenience Sample of US Adults
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.